Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Incurable Hepatocellular Carcinoma
NCT07691762Phase 3Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Nov 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
A Phase 3 trial of CS1002, adebrelimab in hepatocellular carcinoma (HCC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CS1002adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07691762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691762.